Effects of Altitude-like Cognition Training on Neuroplasticity and Cognitive Functions
NCT06121206 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 190
Last updated 2025-09-26
Summary
The goal of this clinical trial is to investigate the effects of a three-week altitude-like cognition training intervention in healthy individuals (substudy 1) and symptomatically stable patients with mood disorders (depression or bipolar disorder; substudy 2). This multi-modal intervention consists of an adaptive cognitive training programme that participants complete while they're inside an altitude-training room with 12% O2, corresponding to 4400 meters altitude.
Across substudy 1 and 2, the investigators hypothesize that altitude-like cognition training has a beneficial effect on cognition after three-weeks treatment completion measured with a global cognition composite score (primary outcome measure). Further, the investigators hypothesize that hypoxia and cognition training will yield improved executive functioning after treatment completion and changes in brain activity during working memory in the dorsal prefrontal cortex 4 weeks after treatment completion (secondary outcome measures). In the patient study, the investigators further hypothesize that the intervention will have beneficial effects on daily-life cognition measured in virtual reality (VR) 4 weeks after treatment completion (secondary outcome measure in substudy 2). For exploratory purposes, the study will examine effects on additional measures of cognition, functioning and self-ratings scales (tertiary outcomes).
The investigators will compare the combination of altitude-like hypoxia (12%) and cognitive training with (1) hypoxia with no training, (2) cognitive training under normal oxygen levels (normoxia; 20%), and (3) normoxia with no training in healthy individuals (substudy 1). For patients with mood disorders (substudy 2) the effects of altitude-like hypoxia (12%) and cognitive training are compared to treatment as usual (TAU).
Conditions
Interventions
- OTHER
-
Altitude-like hypoxia (12% O2)
Fresh air with 12% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. After participants enter the room, the O2 levels will be reduced from 16% to 12% (≈ 4,400 meters altitude) in a 30 minutes lead-in phase. The target O2 level of 12% will be maintained over three hours
- OTHER
-
Normoxia (20% O2)
Fresh air with 20% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. The target O2 level of 20% will be maintained over 3.5 hours
- BEHAVIORAL
-
Cognitive training
The web-based cognitive training (Happy Neuron Pro) is grounded on principles of neuroplasticity-based learning by being intensive, neuroadaptive, engaging and rewarding. The active training involves parametric task adjustment by decreasing stimuli presentation time, increasing working memory load, decreasing time to respond, and increasing the number of non-target items (distractors).
- BEHAVIORAL
-
Sham training
Participants in the no training control condition receive computer games similar to Happy Neuron Pro but with low cognitive demand that produce no cognitive benefits. Specifically, this sham procedure involves the exact same stimuli as the active condition but with changes from trial to trial only in the appearance of the tasks.
Sponsors & Collaborators
- collaborator OTHER
-
University of Copenhagen
collaborator OTHER -
Rigshospitalet, Denmark
collaborator OTHER -
Mental Health Services in the Capital Region, Denmark
lead OTHER
Principal Investigators
-
Kamilla W Miskowiak, DMSc, DPhil · Mental Health Services in the Capital Region, Denmark
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-02-01
- Primary Completion
- 2025-07-01
- Completion
- 2025-07-30
Countries
- Denmark
Study Locations
More Related Trials
-
Treatment of Depression in Adults
NCT00073697 ·Status: COMPLETED ·Phase: PHASE4
-
Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
NCT00220701 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
NCT01422213 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Depression in the Elderly
NCT00130455 ·Status: TERMINATED ·Phase: PHASE4
-
Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders
NCT03278938 ·Status: WITHDRAWN ·Phase: PHASE4
-
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression
NCT02132286 ·Status: COMPLETED ·Phase: PHASE4
-
Optimizing Electroconvulsive Therapy for Depression
NCT00045916 ·Status: COMPLETED ·Phase: PHASE4
-
Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls
NCT01607125 ·Status: COMPLETED ·Phase: PHASE1
-
Repeated Neurocognitive Measurements in Depressed Patients
NCT04916548 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
NCT01368432 ·Status: COMPLETED ·Phase: PHASE2
-
Escitalopram Treatment In Acute Stroke
NCT01561092 ·Status: WITHDRAWN ·Phase: PHASE4
-
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
NCT05768126 ·Status: RECRUITING ·Phase: PHASE4
-
Escitalopram for the Treatment of Depression in Alzheimer's Disease
NCT01841125 ·Status: COMPLETED ·Phase: PHASE4
-
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479 ·Status: COMPLETED ·Phase: PHASE2
-
rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure
NCT00437827 ·Status: COMPLETED ·Phase: NA
-
Depression, Epinephrine, and Platelet Function
NCT00166114 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment Resistant Bipolar Depression
NCT00272025 ·Status: TERMINATED ·Phase: PHASE1
-
Long-term Follow-up of Depressive Disorders in Psychiatric Care
NCT07078227 ·Status: RECRUITING
-
Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes
NCT07087353 ·Status: RECRUITING ·Phase: NA
-
Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder
NCT01541475 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
NCT01564862 ·Status: COMPLETED ·Phase: PHASE2
-
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
NCT02749721 ·Status: COMPLETED ·Phase: PHASE4
-
A Study in Prevention of Re-emergence of Depression Symptoms
NCT01299272 ·Status: COMPLETED ·Phase: PHASE3
-
Changing Tactics? Optimizing ECT in Difficult-to-treat Depression
NCT05923801 ·Status: RECRUITING ·Phase: NA
-
MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults
NCT07077291 ·Status: COMPLETED ·Phase: NA